Johnson & Johnson (JNJ.US) Tatoquimab is planned to be included in priority review in China for inhibiting tumor formation and growth

智通财经2026/09/24 06:51

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

According to information from Zhitong Finance APP, on September 24, the CDE website showed that Johnson & Johnson's (JNJ.US) Talquetamab (Chinese brand name: Tuolike) is proposed to be included in the priority review process. It is intended for use in combination with pomalidomide to treat adult patients with relapsed or refractory multiple myeloma (R/R MM) who have previously received at least one line of therapy (including an anti-CD38 monoclonal antibody and lenalidomide).

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Johnson & Johnson (JNJ.US) Tatoquimab is planned to be included in priority review in China for inhibiting tumor formation and growth

You may also like

Crypto prices